Scribe Therapeutics, Inc.

Nasdaq: SCTX

Day 75 public/EARLY PUBLIC/IPO Jul 27, 2026/Biological Products, (No Diagnostic Substances)

$21.17

▲ 1.94 (+10.09%)

LIVE

updated 17h ago

Intelligence Core

MONITORING

No new filings in 72 h · watching for the next event

Current missionThesis Test · Day 31–90

Test the initial thesis against the first earnings, guidance and execution.

Focus

EarningsGuidanceExecutionInstitutional changes

STRENGTHENINGFORMING THESIS…Intelligence score DERIVED

/ 100

Confidence85%

CURRENT THESIS INTERPRETED

Scribe Therapeutics is exhibiting early-stage public market momentum backed by strong institutional sponsorship and active insider disclosures following its recent IPO. Fundamentals reflect early-stage clinical biotechnology positioning with reported revenue, net loss, and cash reserves.

Momentum

Price · since IPOLIVE

Yahoo · 54 pts

H $37.25L $16.21Last $21.17

Current ThesisINTERPRETEDLIVE

Why

+Institutional ownership demonstrated by 4 Schedule 13D and 13G disclosures
+Positive 1-day price momentum of 10.09% to $21.17
+Active insider reporting with 25 insider forms filed

Risks

−Newly public status under 90 days with elevated risk profile
−Early clinical-stage sector exposure
−Fundamentals characterized by net losses alongside cash burn and reported revenue

Catalysts

→Upcoming regulatory or clinical updates filed via 8-K or 10-Q disclosures
→Continued institutional accumulation following Schedule 13D/13G filings

Current Thesis

Company Web Research · Official DomainVIEW ONLY

https://scribetx.com

VIEW-ONLY

Visit

Capturing scribetx.com…

Screenshot of Scribe Therapeutics, Inc.'s official website

SNAPSHOT · live view blocked by site (X-Frame-Options: SAMEORIGIN)

Resolving official website…

Research EnvironmentLIVE

Research environment · $SCTXSEC · market · news

22 evidence items|newest evidence 4d ago

Core activity · newest firstreal events · view-only

0s agoSCOREDERIVEDIntelligence score 72/100 recomputed from 5 rule-based signals.via Deterministic scoreDERIVED

0s agoSTATECore MONITORING · No new filings in 72 h · watching for the next event. Mission: Thesis Test.via Intelligence Core

17h agoOBSERVATIONVERIFIEDLast price $21.17 · +10.09% on the day.via Finnhub quoteVERIFIED

4d agoEVIDENCECathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Upvia Benzinga · tier 3, cross-check 10d agoEVIDENCE12 Health Care Stocks Moving In Wednesday's Intraday Sessionvia Benzinga · tier 3, cross-check 11d agoEVIDENCECathie Wood Makes $64 Million Bet on Two Stocksvia Yahoo · tier 3, cross-check Sep 2, 2026EVIDENCEVERIFIEDForm 8-K filed · 8-K.via SEC EDGARVERIFIED Sep 2, 2026EVIDENCEVERIFIEDForm 10-Q filed · 10-Q.via SEC EDGARVERIFIED Aug 3, 2026EVIDENCEVERIFIEDForm SCHEDULE 13G filed.via SEC EDGARVERIFIED Jul 30, 2026EVIDENCEVERIFIEDForm SCHEDULE 13D filed.via SEC EDGARVERIFIED Jul 30, 2026EVIDENCEVERIFIEDForm SCHEDULE 13D filed.via SEC EDGARVERIFIED

Evidence · SEC filing timelineVERIFIED

Filed	Form	Document	Source
2026-09-02	10-Q	10-Q	SEC ↗
2026-09-02	8-K	8-K	SEC ↗
2026-08-03	SCHEDULE 13G	Scribe Therapeutics, Inc.	SEC ↗
2026-07-30	SCHEDULE 13D	Scribe Therapeutics, Inc.	SEC ↗
2026-07-30	SCHEDULE 13D	Scribe Therapeutics, Inc.

VERIFIEDfrom a primary sourceDERIVEDcomputed by rulesINTERPRETEDreasoned from evidence

Assembled 0s ago · every panel labelled live or simulated · no fabricated metrics